The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of mice

Pharmacology Biochemistry and Behavior

Volumn 157, Issue , 2017, Pages 47-57

  Zhou, Dongsheng ^a,b   Zhang, Zhongmin ^c   Liu, Lingjiang ^a,b   Li, Chenli ^a,b   Li, Mengmeng ^a,b   Yu, Hanjie ^a,b   Cai, Xiongxiong ^a,b   Sun, Xin ^a,b   Shen, Xinbei ^a,b   Wang, Jinting ^a,b   Geng, Jiacheng ^a,b   Wang, Chuang ^a,b   Shi, Yaosheng ^a,b  

^a Ningbo Kangning Hospital   (China)

^b NINGBO UNIVERSITY   (China)

^c MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

BDNF TrkB signaling; Bicaudal C homolog 1 gene (BICC1); Biperiden; Depression

Indexed keywords

BIPERIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; K 252A; TROPOMYOSIN RELATED KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; BICC1 PROTEIN, MOUSE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CARBAZOLE DERIVATIVE; INDOLE ALKALOID; RNA BINDING PROTEIN; STAUROSPORINE AGLYCONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BICAUDAL C HOMOLOG 1 GENE; CHRONIC UNPREDICTABLE STRESS; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; DRUG ANTAGONISM; GENE; GENE EXPRESSION; HIPPOCAMPUS; LATENT PERIOD; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIPERIDEN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARBAZOLES; DEPRESSION; HIPPOCAMPUS; INDOLE ALKALOIDS; LOCOMOTION; MALE; MICE; MICE, INBRED ICR; PREFRONTAL CORTEX; RECEPTOR, TRKB; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 85013399278     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2017.02.004     Document Type: Article

References (55)

1. Anita, E.A., Monteggia, Lisa M., Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64 (2012), 238–258.
2. Autry, A.E., Adachi, M., Cheng, P., Monteggia, L.M., Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior. Biol. Psychiatry 66 (2009), 84–90.
3. Banerjee, R., Hazra, S., Ghosh, A.K., Mondal, A.C., Chronic administration of bacopa monniera increases BDNF protein and mRNA expressions: a study in chronic unpredictable stress induced animal model of depression. Psychiatry Investig. 11 (2014), 297–306.
4. Bermingham, R., Carballedo, A., Lisiecka, D., Fagan, A., Morris, D., Fahey, C., Donohoe, G., Meaney, J., Gill, M., Frodl, T., Effect of genetic variant in BICC1 on functional and structural brain changes in depression. Neuropsychopharmacology 37 (2012), 2855–2862.
5. Björkholm, C., Monteggia, L.M., BDNF-a key transducer of antidepressant effects. Neuropharmacology 102 (2016), 72–79.
6. Castrén, E., Rantamäki, T., The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 70 (2010), 289–297.
7. Chiou, Y.J., Huang, T.L., Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode major depressive disorder: effects of antidepressants. Int. J. Neuropsychopharmacol., 2016, 10.1093/ijnp/pyw096 (pii: pyw096).
8. Choi, M., Lee, S.H., Wang, S.E., Ko, S.Y., Song, M., Choi, J.S., Kim, Y.S., Duman, R.S., Son, H., Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 15755–15760.
9. Chopra, K., Kumar, B., Kuhad, A., Pathobiological targets of depression. Expert Opin. Ther. Targets 15 (2011), 379–400.
10. Colle, R., Deflesselle, E., Martin, S., David, D.J., Hardy, P., Taranu, A., Falissard, B., Verstuyft, C., Corruble, E., BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. Pharmacogenomics 16 (2015), 997–1013.
11. D'Aquila, P.S., Peana, A.T., Carboni, V., Serra, G., Different effect of desipramine on locomotor activity in quinpirole-treated rats after repeated restraint and chronic mild stress. J. Psychopharmacol. 14 (2000), 347–352.
12. Davidson, S., Stanley, L., Cowie, P., Lear, M., McGuffin, P., Quinn, J.P., Barrett, P., MacKenzie, A., Analysis of the effects of depression associated polymorphisms on the activity of the BICC1 promoter in amygdala neurones. Pharmacogenomics J. 16 (2016), 366–374.
13. Di Liberto, V., Frinchi, M., Verdi, V., Vitale, A., Plescia, F., Cannizzaro, C., Massenti, M.F., Belluardo, N., Mudo, G., Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 levels in the hippocampus and prefrontal cortex. Psychopharmacology, 2016, 10.1007/s00213-016-4498-0.
14. Dilsaver, S.C., Cholinergic mechanisms in depression. Brain Res. 396 (1986), 285–316.
15. Dong, C., Zhang, J.C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., Hashimoto, K., Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int. J. Neuropsychopharmacol., 2016, 10.1093/ijnp/pyw089 (pii: pyw089).
16. Duman, R.S., Aghajanian, G.K., Sanacora, G., Krystal, J.H., Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat. Med. 22 (2016), 238–249.
17. Filho, C.B., Jesse, C.R., Donato, F., Giacomeli, R., Del Fabbro, L., da Silva Antunes, M., de Gomes, M.G., Goes, A.T., Boeira, S.P., Prigol, M., Souza, L.C., Chronic unpredictable mild stress decreases BDNF and NGF levels and Na(+),K(+)-ATPase activity in the hippocampus and prefrontal cortex of mice: antidepressant effect of chrysin. Neuroscience 289 (2015), 367–380.
18. Furey, M.L., Drevets, W.C., Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 63 (2006), 1121–1129.
19. Gazal, M., Ortmann, C.F., Martins, F.A., Streck, E.L., Quevedo, J., de Campos, A.M., Stefanello, F.M., Kaster, M.P., Ghisleni, G., Reginatto, F.H., Lencina, C.L., Antidepressant-like effects of aqueous extract from Cecropia pachystachya leaves in a mouse model of chronic unpredictable stress. Brain Res. Bull. 108 (2014), 10–17.
20. Guilloux, J.P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A.M., Martinowich, K., Tseng, G.C., Lewis, D.A., Sibille, E., Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol. Psychiatry 17 (2012), 1130–1142.
21. Hashikawa-Hobara, N., Ogawa, T., Sakamoto, Y., Matsuo, Y., Ogawa, M., Zamami, Y., Hashikawa, N., Calcitonin gene-related peptide pre-administration acts as a novel antidepressant in stressed mice. Sci. Rep., 5, 2015, 12559.
22. Jiang, B., Xiong, Z., Yang, J., Wang, W., Wang, Y., Hu, Z.L., Wang, F., Chen, J.G., Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br. J. Pharmacol. 6 (2012), 1872–1887.
23. Jiang, B., Song, L., Wang, C.N., Zhang, W., Huang, C., Tong, L.J., Antidepressant-like effects of GM1 ganglioside involving the BDNF signaling cascade in mice. Int. J. Neuropsychopharmacol., 19, 2016.
24. Joca, S.R., Moreira, F.A., Wegener, G., Atypical neurotransmitters and the neurobiology of depression. CNS Neurol. Disord. Drug Targets 14 (2015), 1001–1011.
25. Karege, F., Bondolfi, G., Gervasoni, N., Schwald, M., Aubry, J.M., Bertschy, G., Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 57 (2005), 1068–1072.
26. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., National Comorbidity Survey Replication, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
27. Kraus, M.R., Clauin, S., Pfister, Y., Di Maio, M., Ulinski, T., Constam, D., Bellanne-Chantelot, C., Grapin-Botton, A., Two mutations in human BICC1 resulting in Wnt pathway hyperactivity associated with cystic renal dysplasia. Hum. Mutat. 33 (2012), 86–90.
28. Lepack, A.E., Fuchikami, M., Dwyer, J.M., Banasr, M., Duman, R.S., BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol., 18, 2014.
29. Lepack, A.E., Bang, E., Lee, B., Dwyer, J.M., Duman, R.S., Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology 111 (2016), 242–252.
30. Lewis, C.M., Ng, M.Y., Butler, A.W., Cohen-Woods, S., Uher, R., Pirlo, K., Weale, M.E., Schosser, A., Paredes, U.M., Rivera, M., Craddock, N., Owen, M.J., Jones, L., Jones, I., Korszun, A., Aitchison, K.J., Shi, J., Quinn, J.P., Mackenzie, A., Vollenweider, P., Waeber, G., Heath, S., Lathrop, M., Muglia, P., Barnes, M.R., Whittaker, J.C., Tozzi, F., Holsboer, F., Preisig, M., Farmer, A.E., Breen, G., Craig, I.W., McGuffin, P., Genome-wide association study of major recurrent depression in the U.K. population. Am. J. Psychiatry 167 (2010), 949–957.
31. Lin, P., Wang, C., Xu, B., Gao, S., Guo, J., Zhao, X., Huang, H., Zhang, J., Chen, X., Wang, Q., Zhou, W., The VGF-derived peptide TLQP62 produces antidepressant-like effects in mice via the BDNF/TrkB/CREB signaling pathway. Pharmacol. Biochem. Behav. 120 (2014), 140–148.
32. Lomazzo, E., König, F., Abassi, L., Jelinek, R., Lutz, B., Chronic stress leads to epigenetic dysregulation in the neuropeptide-Y and cannabinoid CB1 receptor genes in the mouse cingulate cortex. Neuropharmacology 113 (2016), 301–313.
33. Ludka, F.K., Zomkowski, A.D., Cunha, M.P., Dai-Cim, T., Zeni, A.L., Rodrigues, A.L., Tasca, C.I., Acute atorvastatin treatment exerts antidepressant like effect in mice via the L-argininenitric oxide–cyclic guanosine monophosphate pathway and increases BDNF levels. Eur. Neuropsychopharmacol. 23 (2013), 400–412.
34. Navarria, A., Wohleb, E.S., Voleti, B., Ota, K.T., Dutheil, S., Lepack, A.E., Dwyer, J.M., Fuchikami, M., Becker, A., Drago, F., Duman, R.S., Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol. Dis. 82 (2015), 254–261.
35. Neto, Fani L., Borges, Gisela, Torres-Sanchez, Sonia, Mico, Juan A., Berrocoso, Esther, Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr. Neuropharmacol. 9 (2011), 530–552.
36. Ota, K.T., Andres, W., Lewis, D.A., Stockmeier, C.A., Duman, R.S., BICC1 expression is elevated in depressed subjects and contributes to depressive behavior in rodents. Neuropsychopharmacology 40 (2015), 711–718.
37. Otsuki, K., Uchida, S., Watanuki, T., Wakabayashi, Y., Fujimoto, M., Matsubara, T., Funato, H., Watanabe, Y., Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 42 (2008), 1145–1153.
38. Piazzon, N., Maisonneuve, C., Guilleret, I., Rotman, S., Constam, D.B., Bicc1 links the regulation of cAMP signaling in polycystic kidneys to microRNA-induced gene silencing. J. Mol. Cell Biol. 4 (2012), 398–408.
39. Pizzorusso, T., Ratto, G.M., Putignano, E., Maffei, L., Brain-derived neurotrophic factor causes cAMP response element-binding protein phosphorylation in absence of calcium increases in slices and cultured neurons from rat visual cortex. J. Neurosci. 20 (2000), 2809–2816.
40. Porsolt, R.D., Le Pichon, M., Jalfre, M., Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977), 730–732.
41. Qi, X.R., Zhao, J., Liu, J., Fang, H., Swaab, D.F., Zhou, J.N., Abnormal retinoid and TrkB signaling in the prefrontal cortex in mood disorders. Cereb. Cortex 25 (2015), 75–83.
42. Schmidt, H.D., Duman, R.S., Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35 (2010), 2378–2391.
43. Smith, M.A., Makino, S., Kvetnanský, R., Post, R.M., Effects of stress on neurotrophic factor expression in the rat brain. Ann. N. Y. Acad. Sci. 771 (1995), 234–239.
44. Szczepanik, J., Nugent, A.C., Drevets, W.C., Khanna, A., Zarate, C.A. Jr., Furey, M.L., Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder. Psychiatry Res. 254 (2016), 67–73.
45. Thompson Ray, M., Weickert, C.S., Wyatt, E., Webster, M.J., Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 36 (2011), 195–203.
46. Tripp, A., Oh, H., Guilloux, J.P., Martinowich, K., Lewis, D.A., Sibille, E., Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am. J. Psychiatry 169 (2012), 1194–1202.
47. Veena, J., Srikumar, B.N., Mahati, K., Raju, T.R., Shankaranarayana Rao, B.S., Oxotremorine treatment restores hippocampal neurogenesis and ameliorates depression-like behavior in chronically stressed rats. Psychopharmacology 217 (2011), 239–253.
48. Voleti, B., Navarria, A., Liu, R.J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., Duman, R.S., Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74 (2013), 742–749.
49. Wang, C., Zhang, J., Lu, Y., Lin, P., Pan, T., Zhao, X., Liu, A., Wang, Q., Zhou, W., Zhang, H.T., Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice. Metab. Brain Dis. 29 (2014), 673–682.
50. Witkin, J.M., Overshiner, C., Li, X., Catlow, J.T., Wishart, G.N., Schober, D.A., Heinz, B.A., Nikolayev, A., Tolstikov, V.V., Anderson, W.H., Higgs, R.E., Kuo, M.S., Felder, C.C., M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J. Pharmacol. Exp. Ther. 351 (2014), 448–456.
51. Wohleb, E.S., Gerhard, D., Thomas, A., Duman, R.S., Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr. Neuropharmacol., 2016.
52. Yan, H.C., Qu, H.D., Sun, L.R., Li, S.J., Cao, X., Fang, Y.Y., Jie, W., Bean, J.C., Wu, W.K., Zhu, X.H., Gao, T.M., Fuzi polysaccharide-1 produces antidepressant-like effects in mice. Int. J. Neuropsychopharmacol. 13 (2010), 623–633.
53. Zhao, G., Zhang, C., Chen, J., Su, Y., Zhou, R., Wang, F., Xia, W., Huang, J., Wang, Z., Hu, Y., Cao, L., Guo, X., Yuan, C., Wang, Y., Yi, Z., Lu, W., Wu, Y., Wu, Z., Hong, W., Peng, D., Fang, Y., Ratio of mBDNF to proBDNF for differential diagnosis of major depressive disorder and bipolar depression. Mol. Neurobiol., 2016.
54. Zhong, P., Wang, W., Pan, B., Liu, X., Zhang, Z., Long, J.Z., Zhang, H.T., Cravatt, B.F., Liu, Q.S., Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39 (2014), 1763–1776.
55. Zhou, L., Ma, S.L., Yeung, P.K., Wong, Y.H., Tsim, K.W., So, K.F., Lam, L.C., Chung, S.K., Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. Transl. Psychiatry, 6, 2016, e881.